<DOC>
	<DOCNO>NCT02300519</DOCNO>
	<brief_summary>Personalized therapy haemophilia reach yet . Treatment substitutive dos base level deficient factor VIII ( haemophilia A ) IX ( haemophilia B ) . The bleed severity relate factor deficiency also level coagulation factor ( e.g . factor X , II , AT TFPI ) . It 's necessary take account order individualize treatment ; Thrombin Generation Assay ( TGA ) CAT method ( Calibrated Automated Thrombography ) good way measure result coagulation cascade . TGA Platelet Rich Plasma ( PRP ) even closer physiological condition Platelet Poor Plasma ( PPP ) platelet influence represent . It already show ( least PPP ) bleeding tendency haemophilic patient usually well correlated TG . Some TG parameter use characterize individual coagulation phenotype , important Endogenous Thrombin Potential ( ETP ) Lag Time ( LT ) . A hemorrhagic profile usually provide long lag time / low ETP . However , study try determine influence coagulation factor inhibitor TG . They do Platelet Poor Plasma ( PPP ) lyophilize plasma . So relation coagulation factor different TG parameter remain determined , especially haemophilic case . It possible , experimentally , find optimal dose factor add measure TG sample different factor VIII IX concentration , method would time consume expensive , especially do haemophilic patient . A good way consist use TG numerical model . For set initial factor level simulate TG associate parameter . It essential validate exist model , especially haemophilic case , order see whether reliable used clinical practice afterwards.The objective study validate thrombin generation numerical model could predict factor VIII IX activity correction reach thrombin generation sufficient avoid bleeding . A comparison TG observe haemophilic patient TG predict model need validate model . In order define 'safe ' TG i.e . sufficient avoid bleeding , normal range TG parameter measure .</brief_summary>
	<brief_title>Thrombin Generation Numerical Models Validation Haemophilic Case</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Signed consent form Age 18 45 year old Male smoker clinical research protocol participation 3 month inclusion Personal familial history hemorrhagic disease ( parent , brother sister Personal history thrombosis ( arterial venous ) Familial history thrombosis 45 year old ( parent , brother sister ) Drug treatment aspirin antiinflammatory type week sample Surgery month sample Chronic pathology responsible inflammatory syndrome Infectious episode course</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Haemophilia</keyword>
	<keyword>numerical model</keyword>
	<keyword>thrombin generation</keyword>
	<keyword>volunteer</keyword>
	<keyword>endogenous thrombin potential</keyword>
</DOC>